This phase III trial studies how well tenofovir alafenamide works in preventing liver
complications in participants with current or past hepatitis B virus (HBV) who are receiving
anti-cancer therapy for solid tumors. People with chronic or past HBV who are undergoing
therapy for cancer are at an increased risk for changes in the liver which could be minor or
severe. Tenofovir alafenamide is a drug that acts against infections caused by HBV and may
help reduce the chance that HBV gets worse or comes back in participants receiving
anti-cancer therapy for solid tumors.
Intervention
Best Practice, Entecavir, Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate
Condition
Hepatitis B Virus Positive, Malignant Solid Neoplasm
Investigators
Jessica P Hwang, Jay W. Carlson, Gary L. Buchschacher, Jennifer M. Suga, Lisa Bailey, Pankaj Gupta, Irene Kang, Howard A. Zaren, Jeffrey L. Berenberg, John M. Schallenkamp, Priyank P. Patel, Mary F. Mulcahy, David M. King, John C. Henegan, Rachael A. Safyan, Jessica P. Hwang